agilon health, inc. AGL R2KR3KPHARMA
Company Overview
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. The company was founded in 2016 and is based in Westerville, Ohio.
Why Investors Should Care
Revenue has grown at a 39.8% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.15.
Recent Developments
- Dec 2025 Revenue of $5.93B (-2.1% YoY); net profit $-391.35M.
- Trailing 12 Months Year-on-year growth — revenue +7.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 39.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 39.81% |
| 1 Year: | 7.20% |
Stock Price Performance
| 1 Year: | +237.14% |
| 6 Months: | +491.97% |
| 3 Months: | -8.62% |
| 1 Month: | +1.92% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)42.98 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 39.8% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 31.8% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AGL agilon health, inc. R2KR3KPHARMA | 88.50 | -5.81 | $1.49B | 0.00% | - | -78.94% | 39.81% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 291.05M | 293.59M | 312.68M | 413.10M | 498.96M | 458.61M | 653.45M | 670.13M | 694.86M | 1.05B | 1.07B | 1.14B | 1.60B | 1.48B | 1.45B | - | 1.53B | 1.39B | 1.44B | 1.57B | 1.42B | 1.49B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.48B | 1.45B | 1.50B | 1.66B | 1.36B | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 50.72M | -52.43M | -67.65M | -90.67M | 65.02M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 72.83M | 63.60M | 63.63M | 67.07M | 61.02M | - |
| Operating Income | -5.83M | -1.25M | -9.84M | -12.12M | -298.36M | -35.60M | -743.00K | -21.05M | -29.52M | 417.00K | -28.96M | -39.29M | -7.18M | -43.34M | -133.51M | - | -22.11M | -116.03M | -131.27M | -157.74M | 4.00M | 11.77M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.70M | -95.42M | -101.27M | -178.87M | 38.54M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.51M | 1.57M | 1.84M | 1.72M | 1.81M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.69M | -104.31M | -110.54M | -187.56M | 29.94M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 196.00K | 62.00K | -331.00K | 1.32M | 28.00K | - |
| Net Income | -16.10M | -7.91M | -11.83M | -15.08M | -298.85M | -35.84M | 1.23M | -20.65M | -30.67M | 16.02M | -16.75M | -31.44M | -6.06M | -30.68M | -117.61M | - | 12.11M | -104.37M | -110.21M | -188.88M | 48.92M | 17.96M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.73 | -6.25 | -6.75 | -11.50 | 2.94 | 1.04 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 794.41M | 1.22B | 1.52B | 2.39B | 4.32B | 6.06B | 5.93B |
| Cost of Revenue | - | - | - | 2.28B | 4.25B | 6.06B | 6.09B |
| Gross Profit | - | - | - | 111.36M | 69.67M | 4.84M | -160.02M |
| Operating Expenses | - | - | - | 216.74M | 301.80M | 293.38M | 267.13M |
| Operating Income | -106.57M | -56.67M | -372.24M | -105.38M | -232.13M | -288.53M | -427.15M |
| EBITDA | - | - | - | -72.41M | -167.64M | -218.19M | -368.86M |
| Interest Expense | - | - | - | 4.48M | 6.66M | 6.18M | 6.64M |
| Pretax Income | - | - | - | -90.67M | -194.46M | -248.83M | -404.10M |
| Tax Provision | - | - | - | 1.64M | 791.00K | 1.45M | 1.25M |
| Net Income | -282.59M | -60.05M | -406.49M | -106.55M | -262.60M | -260.15M | -391.35M |
| Diluted EPS | - | - | - | -6.50 | -16.00 | -15.75 | -23.75 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 446.36M | - | 1.70B | 1.74B | 1.73B | 1.27B |
| Current Assets | - | - | - | - | 1.45B | 1.48B | 1.46B | 1.10B |
| Cash & Equivalents | - | - | 106.80M | - | 465.30M | 107.57M | 188.23M | 173.71M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 492.36M | 942.46M | 1.02B | 673.79M |
| Total Liabilities | - | - | 421.59M | - | 656.86M | 1.08B | 1.26B | 1.14B |
| Current Liabilities | - | - | 266.83M | - | 535.09M | 977.16M | 1.15B | 1.08B |
| Long Term Debt | - | - | 64.67M | - | 38.48M | 32.31M | 34.90M | 15.75M |
| Total Debt | - | - | - | - | 52.57M | 43.21M | 41.50M | 36.81M |
| Total Equity | 41.60M | -232.03M | -284.73M | - | 1.04B | 661.84M | 470.95M | 126.73M |
| Shares Outstanding | - | - | - | - | 16.50M | 16.26M | 16.49M | 16.59M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -103.86M | -53.20M | - | -130.81M | -156.20M | -57.78M | -105.76M |
| Investing Cash Flow | -5.06M | 22.07M | - | -444.39M | -44.02M | 139.89M | 88.61M |
| Financing Cash Flow | 176.30M | 24.62M | - | 28.06M | -193.13M | -2.58M | -2.99M |
| Capital Expenditure | -2.89M | -1.77M | - | -32.66M | -30.82M | -41.28M | -43.11M |
| Free Cash Flow | -106.75M | -54.98M | - | -163.47M | -187.01M | -99.06M | -148.87M |
| Net Change in Cash | - | - | - | -547.14M | -393.35M | 79.53M | -20.15M |
| Share Buybacks | - | 6.70M | - | - | 200.00M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 4.7% | 1.6% | 0.1% | -2.7% |
| Operating Margin % | -13.4% | -4.7% | -24.5% | -4.4% | -5.4% | -4.8% | -7.2% |
| Net Margin % | -35.6% | -4.9% | -26.7% | -4.5% | -6.1% | -4.3% | -6.6% |
| ROE % | 121.8% | 21.1% | - | -10.2% | -39.7% | -55.2% | -308.8% |
| ROCE % | - | -31.6% | - | -9.1% | -30.4% | -49.6% | -219.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Clayton, Dubilier & Rice, LLC | 23.82% | 4.00M | $370.16M |
| 2 | Morgan Stanley | 11.98% | 2.01M | $186.12M |
| 3 | North Peak Capital Management, Llc | 8.84% | 1.49M | $137.43M |
| 4 | Blackrock Inc. | 6.83% | 1.15M | $106.10M |
| 5 | AQR Capital Management, LLC | 4.12% | 692.54K | $64.09M |
| 6 | Goldman Sachs Group Inc | 4.09% | 686.79K | $63.56M |
| 7 | Vanguard Capital Management LLC | 3.13% | 525.33K | $48.61M |
| 8 | Marshall Wace LLP | 2.79% | 468.29K | $43.34M |
| 9 | Durable Capital Partners Lp | 2.62% | 440.64K | $40.78M |
| 10 | Shaw D.E. & Co., Inc. | 2.32% | 390.15K | $36.10M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AGL
Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year?
Here is how Agilon Health (AGL) and Illumina (ILMN) have performed compared to their sector so far this year.
agilon health Announces Revised Presentation Time at the 2026 Jefferies Healthcare Services and Technology Conference
WESTERVILLE, Ohio, August 27, 2026--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that its management team will now participate in a fireside chat at …
agilon health to Participate in Upcoming Conferences
WESTERVILLE, Ohio, August 20, 2026--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that its management team will participate in a fireside chat at the …
5 Insightful Analyst Questions From agilon health’s Q2 Earnings Call
Agilon Health’s second quarter was marked by significant beats on both revenue and profitability, but the results did not prevent a notable drop in the company’s share price. Management attributed the quarter’s strong financials to operatio…
Agilon Health (AGL) Q2 2026 Earnings Call Transcript
Revenue hit $1.49 billion as medical margins swung sharply positive.
Has Agilon Health (AGL) Outpaced Other Medical Stocks This Year?
Here is how Agilon Health (AGL) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
AGL — Frequently Asked Questions
What is the current share price of agilon health, inc. (AGL)?
As of 2026-09-07 16:24 PDT, agilon health, inc. (AGL) trades at $88.50 on NYSE. Its 52-week range is $7.91 to $129.84.
What is the market capitalisation of AGL?
agilon health, inc. (AGL) has a market capitalisation of $1.49B on NYSE.
What is the P/E ratio of AGL?
AGL trades at a trailing price-to-earnings (P/E) ratio of -5.81. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 7.05.
What is the return on equity (ROE) of AGL?
AGL has a return on equity (ROE) of -78.94%.
Is AGL a good stock to buy?
This page provides a data-driven analysis of agilon health, inc. (AGL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.